submitted
This commit is contained in:
parent
eae343e574
commit
509b3c2b54
121
coursework.lyx
121
coursework.lyx
@ -143,11 +143,11 @@ f=\frac{c}{\lambda}
|
||||
\end_layout
|
||||
|
||||
\begin_layout Standard
|
||||
Therefore in order to find the
|
||||
Therefore in order to find the energy,
|
||||
\begin_inset Formula $E$
|
||||
\end_inset
|
||||
|
||||
in terms of wavelength
|
||||
, in terms of wavelength
|
||||
\end_layout
|
||||
|
||||
\begin_layout Standard
|
||||
@ -183,7 +183,7 @@ This energy value will be the same as the total interband transition for
|
||||
\begin_layout Standard
|
||||
\begin_inset Formula
|
||||
\begin{equation}
|
||||
E_{g,transition}=E_{1h}+E_{g}+E_{1e}\thickapprox0.800\unit{eV}\label{eq:Energy-Gap-Sum}
|
||||
E_{g,transition}=E_{1h}+E_{g,bulk}+E_{1e}\thickapprox0.800\unit{eV}\label{eq:Energy-Gap-Sum}
|
||||
\end{equation}
|
||||
|
||||
\end_inset
|
||||
@ -522,8 +522,8 @@ Applying this to the prospective well material gives the following,
|
||||
\end_layout
|
||||
|
||||
\begin_layout Standard
|
||||
This shows that to 4 significant figures the composition of InGaAs is lattice
|
||||
matched to InP to within 0.001Å which is sufficient for this application.
|
||||
This shows that this combination of InGaAs is lattice matched to InP to
|
||||
within 0.001Å, a sufficient offset for this application.
|
||||
\end_layout
|
||||
|
||||
\begin_layout Subsection
|
||||
@ -755,7 +755,7 @@ Having found two materials that are lattice matched with a suitable band
|
||||
\emph on
|
||||
\begin_inset Formula
|
||||
\begin{equation}
|
||||
E_{n}=\frac{n^{2}\pi^{2}\mathcal{\text{\emph{ħ}}}^{2}}{2mL^{2}}\label{eq:Energy-levels}
|
||||
E_{n}=\frac{n^{2}\pi^{2}\mathcal{\text{ħ}}^{2}}{2mL^{2}}\label{eq:Energy-levels}
|
||||
\end{equation}
|
||||
|
||||
\end_inset
|
||||
@ -791,7 +791,7 @@ noprefix "false"
|
||||
\begin_layout Standard
|
||||
\begin_inset Formula
|
||||
\[
|
||||
E_{g,transition}=0.8\unit{eV}=E_{1h}+E_{g,InGaAs}+E_{1e}=\frac{1^{2}\pi^{2}\text{\emph{ħ}}^{2}}{2m_{h}^{*}L^{2}}+E_{g,InGaAs}+\frac{1^{2}\pi^{2}\text{\emph{ħ}}^{2}}{2m_{e}^{*}L^{2}}
|
||||
E_{g,transition}=E_{1h}+E_{g,InGaAs}+E_{1e}=\frac{1^{2}\pi^{2}\text{\emph{ħ}}^{2}}{2m_{h}^{*}L^{2}}+E_{g,InGaAs}+\frac{1^{2}\pi^{2}\text{\emph{ħ}}^{2}}{2m_{e}^{*}L^{2}}=0.8\unit{eV}
|
||||
\]
|
||||
|
||||
\end_inset
|
||||
@ -1095,7 +1095,7 @@ For confined electron states:
|
||||
\emph on
|
||||
\begin_inset Formula
|
||||
\[
|
||||
E_{1e}=\frac{1^{2}\pi^{2}\text{\emph{ħ}}^{2}}{2\cdotp m_{e}^{*}\cdotp\left(14.87\unit{nm}\right)^{2}}
|
||||
E_{1e}=\frac{1^{2}\pi^{2}\text{ħ}^{2}}{2\cdotp m_{e}^{*}\cdotp\left(14.87\unit{nm}\right)^{2}}
|
||||
\]
|
||||
|
||||
\end_inset
|
||||
@ -1159,7 +1159,7 @@ For confined hole states:
|
||||
\emph on
|
||||
\begin_inset Formula
|
||||
\[
|
||||
E_{1h}=\frac{1^{2}\pi^{2}\text{\emph{ħ}}^{2}}{2\cdotp m_{h}^{*}\cdotp\left(14.87\unit{nm}\right)^{2}}
|
||||
E_{1h}=\frac{1^{2}\pi^{2}\text{ħ}^{2}}{2\cdotp m_{h}^{*}\cdotp\left(14.87\unit{nm}\right)^{2}}
|
||||
\]
|
||||
|
||||
\end_inset
|
||||
@ -1241,7 +1241,8 @@ status open
|
||||
\begin_inset Caption Standard
|
||||
|
||||
\begin_layout Plain Layout
|
||||
InP/InGaAs/InP quantum well design
|
||||
InP/InGaAs/InP quantum well design, relative confined energy level heights
|
||||
are not to scale
|
||||
\begin_inset CommandInset label
|
||||
LatexCommand label
|
||||
name "fig:quantum-well-design"
|
||||
@ -1310,7 +1311,7 @@ Here
|
||||
\begin_layout Standard
|
||||
\begin_inset Formula
|
||||
\[
|
||||
\int_{{\textstyle all\:space}}\psi^{*}\psi dV=1
|
||||
\int_{{\textstyle all\;space}}\psi^{*}\psi dV=1
|
||||
\]
|
||||
|
||||
\end_inset
|
||||
@ -1340,7 +1341,7 @@ in this case providing the wave function
|
||||
\begin_layout Standard
|
||||
Importantly, the above conditions are for an infinite quantum well where
|
||||
an assumption is made that the well has a barrier region of infinite potential
|
||||
such that the wavefunction is confined to the well.
|
||||
such that the wavefunction is confined within the well.
|
||||
A real quantum well is unable to satisfy this leading to the wavefunction
|
||||
|
||||
\begin_inset Quotes eld
|
||||
@ -1750,13 +1751,13 @@ Conclusions
|
||||
Considering these two probabilities it is clear that it is more likely for
|
||||
the electron to be found between 6nm and 8nm than between 2nm and 4nm across
|
||||
the well.
|
||||
This is as expected considering 6nm to 8nm places the interval towards
|
||||
the center of the 14.87nm well.
|
||||
This would be expected considering 6nm to 8nm places the interval towards
|
||||
the center of the 14.87nm long well.
|
||||
As the probability density function is a
|
||||
\begin_inset Formula $\sin^{2}$
|
||||
\end_inset
|
||||
|
||||
function, the maxium area will be towards the center.
|
||||
function, the majority of the area will be towards the center.
|
||||
Referring to figure
|
||||
\begin_inset CommandInset ref
|
||||
LatexCommand ref
|
||||
@ -1795,8 +1796,8 @@ Paclitaxel
|
||||
\end_layout
|
||||
|
||||
\begin_layout Standard
|
||||
Paclitaxel is a chemotherapy drug in the taxane family which function as
|
||||
mitotic inhibitors.
|
||||
Paclitaxel is a chemotherapy drug in the taxane family which together function
|
||||
as mitotic inhibitors.
|
||||
This involves the suppression of mitosis or cell division by preventing
|
||||
the breakdown of the microtubules helping provide structure to cells.
|
||||
|
||||
@ -1805,14 +1806,14 @@ Paclitaxel is a chemotherapy drug in the taxane family which function as
|
||||
\begin_layout Standard
|
||||
This is effective in treating cancer as constant, unmitigated cell mitosis
|
||||
is how cancer spreads throughout the body, blocking this process causes
|
||||
it to die without reproducing.
|
||||
the cells to die without reproducing.
|
||||
\end_layout
|
||||
|
||||
\begin_layout Standard
|
||||
While taxanes are an effective cancer treatment, their use is made less
|
||||
efficacious due to their particularly insolubility in water requiring additiona
|
||||
l chemcials to act as a delivery vehicle in order to allow a solution to
|
||||
be created for intraveneous application.
|
||||
efficacious due to their practical insolubility in water.
|
||||
In order to allow intravenous treatment, additional chemicals must be used
|
||||
as delivery 'vehicles' to improve solubility.
|
||||
\end_layout
|
||||
|
||||
\begin_layout Standard
|
||||
@ -1859,9 +1860,9 @@ As a result of the poor water solubility of taxanes and paclitaxel, a method
|
||||
for delivering a solution was required.
|
||||
Polyethoxylated castor oil (commercially known as Kolliphor EL, formerly
|
||||
Cremophor EL [CrEL]) combined with dehydrated ethanol provides a suitable
|
||||
formulation vehicle for many poorly water soluble and lipophilic drugs
|
||||
and has been the standard for many forms of commercially available paclitaxel
|
||||
such as Taxol.
|
||||
formulation vehicle for many poorly water soluble and lipophilic (tending
|
||||
to dissolve in lipids or fats) drugs and has been the standard for many
|
||||
forms of commercially available paclitaxel such as Taxol.
|
||||
\end_layout
|
||||
|
||||
\begin_layout Standard
|
||||
@ -1907,8 +1908,8 @@ literal "false"
|
||||
|
||||
and is part of the albumin protein family.
|
||||
HSA is produced by the liver and performs important functions such as maintaini
|
||||
ng oncotic pressure in the blood vessels, ensuring the right levels of fluids
|
||||
are found between blood vessels and body tissues, and transporting hormones
|
||||
ng oncotic pressure in the blood vessels (ensuring the right levels of fluids
|
||||
are found between blood vessels and body tissues) and transporting hormones
|
||||
and fatty acids around the body.
|
||||
\end_layout
|
||||
|
||||
@ -1980,19 +1981,11 @@ literal "false"
|
||||
of using a native biological subtance.
|
||||
\end_layout
|
||||
|
||||
\begin_layout Standard
|
||||
The nanoparticles are biodegradable as nano particles of the sizes 10-100nm
|
||||
can be shown to enter the capillaries and be expelled as part of normal
|
||||
cell clearance.
|
||||
\end_layout
|
||||
|
||||
\begin_layout Standard
|
||||
While HSA is frequently used due to it's native presence in the body reducing
|
||||
the chances of an immunologic response, suitable albumin can also be found
|
||||
in egg whites (ovalbumin [OVA]) and bovine serum (bovine serum albumin
|
||||
[BSA]) where abundance and low cost are advantages.
|
||||
Many of the advantages provided by using albumin can be attributed to using
|
||||
a biological protein.
|
||||
\end_layout
|
||||
|
||||
\begin_layout Section
|
||||
@ -2002,9 +1995,55 @@ NAB-Paclitaxel
|
||||
\begin_layout Standard
|
||||
While there are many ways to produce albumin nanoparticles including desolvation
|
||||
, emulsification and thermal gelation, an albumin specific technology was
|
||||
developed in order to capture lipophilic (tending to dissolve in lipids
|
||||
or fats) drugs in albumin nanoparticles known as NAB-technology where NAB
|
||||
refers to nanoparticle albumin-bound.
|
||||
developed in order to capture lipophilic drugs in albumin nanoparticles
|
||||
known as NAB-technology where NAB refers to nanoparticle albumin-bound.
|
||||
\end_layout
|
||||
|
||||
\begin_layout Standard
|
||||
\begin_inset Float figure
|
||||
wide false
|
||||
sideways false
|
||||
status open
|
||||
|
||||
\begin_layout Plain Layout
|
||||
\align center
|
||||
\begin_inset Graphics
|
||||
filename nab-pac.png
|
||||
lyxscale 30
|
||||
width 60col%
|
||||
|
||||
\end_inset
|
||||
|
||||
|
||||
\end_layout
|
||||
|
||||
\begin_layout Plain Layout
|
||||
\begin_inset Caption Standard
|
||||
|
||||
\begin_layout Plain Layout
|
||||
Diagram showing albumin nanoparticles in combination with paclitaxel
|
||||
\begin_inset CommandInset citation
|
||||
LatexCommand cite
|
||||
key "veeda_edge"
|
||||
literal "false"
|
||||
|
||||
\end_inset
|
||||
|
||||
|
||||
\end_layout
|
||||
|
||||
\end_inset
|
||||
|
||||
|
||||
\end_layout
|
||||
|
||||
\begin_layout Plain Layout
|
||||
|
||||
\end_layout
|
||||
|
||||
\end_inset
|
||||
|
||||
|
||||
\end_layout
|
||||
|
||||
\begin_layout Standard
|
||||
@ -2164,8 +2203,14 @@ The landscape is further broadening with research being completed into applying
|
||||
rapamycin.
|
||||
\end_layout
|
||||
|
||||
\begin_layout Standard
|
||||
Drug delivery is one of the largest areas within the field of nanomedicine
|
||||
with other sectors including direct cancer treatment, medical imaging and
|
||||
blood purification.
|
||||
\end_layout
|
||||
|
||||
\begin_layout Paragraph*
|
||||
Part II Word Count:
|
||||
Part II Word Count: 989
|
||||
\end_layout
|
||||
|
||||
\begin_layout Standard
|
||||
|
BIN
coursework.pdf
BIN
coursework.pdf
Binary file not shown.
BIN
nab-pac.png
Normal file
BIN
nab-pac.png
Normal file
Binary file not shown.
After Width: | Height: | Size: 84 KiB |
@ -150,5 +150,7 @@ abstract = "Protein misfolding and self-assembly of disease-related and disease-
|
||||
}
|
||||
|
||||
@book{epar_summary_for_the_public-abraxane_2015,
|
||||
title={European Public Assessment Report Summary - Abraxane}, url={https://www.ema.europa.eu/en/medicines/human/EPAR/abraxane}, journal={ European Medicines Agency}, publisher={ European Medicines Agency}, year={2008}, month={Jan}}
|
||||
title={European Public Assessment Report Summary - Abraxane}, url={https://www.ema.europa.eu/en/medicines/human/EPAR/abraxane}, journal={ European Medicines Agency}, publisher={ European Medicines Agency}, year={2008}, month={Jan}}
|
||||
|
||||
@misc{veeda_edge, title={Protein bound Nano Particles Quantitative bioassays for Total and Unbounded fraction}, url={https://www.veedacr.com/2017/flyers/Protein bound nano particles/Protein bound nano particles.html}, journal={Veeda Edge}}
|
||||
|
||||
|
Loading…
Reference in New Issue
Block a user